Xu Xuehong, Su Bing, Barndt Robert J, Chen Hanying, Xin Hongbo, Yan Guifan, Chen Linyuan, Cheng Dongsheng, Heitman Joseph, Zhuang Yuan, Fleischer Sidney, Shou Weinian
Herman B. Wells Center for Pediatric Research, Riley Hospital for Children, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Transplantation. 2002 Jun 15;73(11):1835-8. doi: 10.1097/00007890-200206150-00023.
FK506-binding proteins (FKBP) are immunophilins that interact with the immunosuppressive drugs FK506 and rapamycin. Several FKBP family members such as FKBP12, FKBP12.6, and FKBP51 are expressed in T cells. It has been speculated that these FKBPs are possibly redundant in the immunosuppressant-induced T-cell inactivation. To determine the pharmacological relevance of multiple FKBP members in the immunosuppressant-induced T-cell inactivation, we have investigated the physiological responses of FKBP12-deficient and FKBP12.6-deficient mutant T cells to the immunosuppressive agent FK506.
FKBP12-deficient and FKBP12.6-deficient T cells were isolated from genetically engineered FKBP12-deficient and FKBP12.6-deficient mice, respectively. T-cell growth inhibitory assay was used to assess their responses to immunosuppressant FK506 treatments.
We found that growth inhibition induced by FK506 is abolished in FKBP12-deficient cells but not in FKBP12.6-deficient cells.
FKBP12 is the only FKBP family member that plays a key role in immunosuppressant-mediated immunosuppression.
FK506结合蛋白(FKBP)是亲免素,可与免疫抑制药物FK506和雷帕霉素相互作用。几种FKBP家族成员,如FKBP12、FKBP12.6和FKBP51,在T细胞中表达。据推测,这些FKBP在免疫抑制剂诱导的T细胞失活中可能是多余的。为了确定多个FKBP成员在免疫抑制剂诱导的T细胞失活中的药理学相关性,我们研究了FKBP12缺陷型和FKBP12.6缺陷型突变T细胞对免疫抑制剂FK506的生理反应。
分别从基因工程改造的FKBP12缺陷型和FKBP12.6缺陷型小鼠中分离出FKBP12缺陷型和FKBP12.6缺陷型T细胞。采用T细胞生长抑制试验评估它们对免疫抑制剂FK506处理的反应。
我们发现,FK506诱导的生长抑制在FKBP12缺陷型细胞中被消除,但在FKBP12.6缺陷型细胞中未被消除。
FKBP12是唯一在免疫抑制剂介导的免疫抑制中起关键作用的FKBP家族成员。